Hermetica Superfood Encyclopedia
The Short Answer
Folinic acid (5-formyl tetrahydrofolic acid, CAS 58-05-9) is a pre-reduced, biologically active folate derivative that enters one-carbon metabolism directly as tetrahydrofolate without requiring DHFR or MTHFR enzymatic activation, enabling immediate participation in thymidylate synthesis, purine biosynthesis, and homocysteine remethylation. It is FDA-approved in combination with 5-fluorouracil for palliative colorectal cancer treatment, where it increases reduced folate pools to stabilize the thymidylate synthase inhibitory ternary complex, enhancing cytotoxic efficacy in the third-leading cause of cancer-related mortality.
CategoryVitamin
GroupMineral
Evidence LevelPreliminary
Primary Keywordfolinic acid benefits
Folinic Acid — botanical close-up
Health Benefits
**MTHFR Bypass and Folate Repletion**
Folinic acid bypasses both dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) enzymatic steps, making it bioavailable to individuals with common MTHFR polymorphisms (C677T, A1298C) who cannot efficiently convert synthetic folic acid to active folate derivatives.
**One-Carbon Metabolism Support**
As a direct precursor to tetrahydrofolate (THF), folinic acid donates one-carbon units essential for de novo purine and thymidylate synthesis, supporting rapid cell division, DNA replication, and repair processes across all tissues.
**Homocysteine Regulation**
By providing active folate for the methionine synthase reaction, folinic acid supports the remethylation of homocysteine to methionine, contributing to maintenance of healthy plasma homocysteine levels and downstream S-adenosylmethionine (SAM) production for methylation reactions.
**Methotrexate Rescue**
In clinical oncology and rheumatology, folinic acid (as leucovorin) rescues normal cells from methotrexate-induced DHFR inhibition by entering cells via the reduced folate carrier and replenishing intracellular THF pools, mitigating mucositis, myelosuppression, and hepatotoxicity.
**Cancer Chemotherapy Potentiation**
In combination with 5-fluorouracil (5-FU), folinic acid elevates intracellular 5,10-methylenetetrahydrofolate concentrations, stabilizing the covalent ternary inhibitory complex with thymidylate synthase and fluorodeoxyuridylate (FdUMP), amplifying DNA synthesis disruption in tumor cells.
**Neurological and Neurodevelopmental Support**
Active folate derivatives supported by folinic acid are critical for neural tube closure, fetal brain development, and neurotransmitter synthesis (e.g., serotonin, dopamine precursors require one-carbon units), with folinic acid being investigated in cerebral folate deficiency syndromes.
**DNA Integrity and Methylation Homeostasis**
Adequate folinic acid-derived THF prevents uracil misincorporation into DNA by ensuring sufficient thymidylate availability, and supports global and gene-specific DNA methylation patterns through the SAM/SAH cycle, relevant to epigenetic stability.
Origin & History
Natural habitat
Folinic acid is a naturally occurring, reduced form of folate (vitamin B9) found endogenously in human tissues and in small amounts in folate-rich foods such as dark leafy greens, liver, and legumes. Unlike synthetic folic acid, it exists in a biologically pre-reduced state and does not require enzymatic conversion by dihydrofolate reductase (DHFR) to become metabolically active. The pharmaceutical form, leucovorin, is synthesized chemically and has been used in clinical oncology since the mid-20th century, though its natural counterpart is distributed ubiquitously in mammalian biochemistry.
“Folinic acid has no history of use in traditional herbal or ethnobotanical medicine systems; its identification as a distinct folate derivative emerged from mid-20th century biochemistry, following the isolation of folic acid by Mitchell, Snell, and Williams in 1941 and subsequent characterization of reduced folate intermediates. The pharmaceutical form, leucovorin (from the Latin 'leucos' meaning white, and 'corin' referencing its structural relationship to cobalamin cofactors), was developed in the 1950s–1960s specifically to counteract antifolate drug toxicity as methotrexate entered oncology practice. Its role as a chemotherapy modulator was cemented through clinical development in the 1980s when combination 5-FU/leucovorin protocols demonstrated superior efficacy over 5-FU monotherapy in colorectal cancer trials, fundamentally reshaping gastrointestinal oncology practice. Contemporary interest in folinic acid as a nutritional supplement — distinct from its pharmaceutical leucovorin role — has grown with increased public awareness of MTHFR polymorphisms and their implications for synthetic folic acid metabolism, though this represents a modern, evidence-evolving application rather than a traditional use.”Traditional Medicine
Scientific Research
The clinical evidence base for folinic acid is strongest in oncology: it holds FDA approval as a pharmacological agent for potentiating 5-FU in colorectal cancer and for leucovorin rescue following high-dose methotrexate, supported by multiple large randomized controlled trials conducted since the 1980s and summarized in systematic reviews. Evidence for folinic acid as a nutritional supplement for MTHFR-related folate insufficiency or general folate repletion is more limited, with no large independent RCTs specific to folinic acid supplementation in healthy populations; much of the mechanistic rationale is extrapolated from folate biochemistry and MTHFR genetics literature. A notable gap exists in direct head-to-head comparative RCTs of folinic acid versus methylfolate (5-MTHF) for nutritional use, though studies on related active folate forms (e.g., L-5-MTHF/Optifolin+) have demonstrated 2.6-fold greater bioavailability and over 240% higher folate status versus synthetic folic acid in crossover trials. For cerebral folate deficiency, case series and small open-label studies support folinic acid efficacy, but large randomized trials remain lacking, placing nutritional evidence at a moderate-to-preliminary tier despite robust pharmacological data.
Preparation & Dosage
Traditional preparation
**Oral Tablet/Capsule (Nutritional Supplement)**
000 mcg per dose for general folate support; dosing for MTHFR support commonly ranges 400–800 mcg/day, though no established RCT-derived optimal dose exists for this indication
Typically 200–1,.
**Oral Leucovorin (Clinical/Pharmaceutical)**
5–25 mg/day orally for folinic acid supplementation in methotrexate-treated rheumatology patients; doses of 10–200 mg/m² used in oncology rescue protocols depending on methotrexate dose and serum levels
**Intravenous Leucovorin (Oncology)**
200–500 mg/m² IV infusion in combination with 5-FU regimens (e
g., FOLFOX, FOLFIRI); IV route provides greater tissue distribution than oral due to bypassed first-pass hepatic metabolism.
**Timing — Methotrexate Rescue**
Must be initiated within 24–42 hours of high-dose methotrexate administration and continued until serum methotrexate falls below 0.05 µmol/L; premature administration may reduce methotrexate efficacy.
**Timing — Nutritional Use**
Best taken with or without food; no strong evidence for time-of-day optimization; separate from antifolate medications by several hours.
**Stability Note**
Parenteral solutions are light-sensitive and unstable; prepare fresh and use within recommended windows per pharmaceutical guidelines.
**Standardization**
Pharmaceutical leucovorin is standardized to the active levo (6S) enantiomer; supplement forms should specify the (6S)-5-formyl-THF isomer for confirmed bioactivity.
Nutritional Profile
Folinic acid is not consumed in meaningful quantities as a dietary macronutrient or isolated micronutrient through food; it exists endogenously in small amounts within the pool of reduced folate derivatives in folate-rich foods (liver, spinach, asparagus, lentils), which collectively provide mixed polyglutamate forms of THF derivatives including 5-methyl-THF, 5-formyl-THF, and 10-formyl-THF. As a pure compound, folinic acid (C20H23N7O7, MW 473.44 Da) contains no caloric macronutrients, lipids, or minerals; its nutritional relevance is purely as a B-vitamin (B9) derivative providing one-carbon metabolic capacity. Bioavailability of folinic acid as a supplement is high relative to synthetic folic acid: it is absorbed via reduced folate carrier-mediated transport in the proximal jejunum, with oral bioavailability described as rapid and nearly complete at lower doses but dose-dependent saturation occurring at higher intakes, and a plasma half-life of approximately 6 hours. The levo (6S) enantiomer is the biologically active form; racemic leucovorin preparations contain 50% inactive (6R) enantiomer, while levoleucovorin preparations provide only the active isomer at half the total dose.
How It Works
Mechanism of Action
Folinic acid (5-formyl-THF) is taken up by cells via the reduced folate carrier (RFC/SLC19A1) and folate receptor proteins, and is enzymatically converted to 5,10-methenyl-THF and then to other THF derivatives without requiring activation by DHFR or MTHFR, directly replenishing the cellular reduced folate pool. Once converted to 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase (SHMT), it serves as the one-carbon donor for thymidylate synthase (TYMS), catalyzing the methylation of deoxyuridylate (dUMP) to thymidylate (dTMP) — a rate-limiting step in DNA synthesis — and also feeds into the folate cycle for de novo purine biosynthesis via ATIC and GART enzymes. In the context of 5-FU co-administration, elevated 5,10-methylenetetrahydrofolate forms a stable, covalent ternary complex with TYMS and FdUMP (the active 5-FU metabolite), allosterically locking the enzyme in an inhibited state and amplifying thymidylate depletion and S-phase cytotoxicity. Additionally, 5-methyl-THF generated downstream supports methionine synthase (MTR)-catalyzed homocysteine remethylation, contributing to SAM biosynthesis and broad cellular methylation capacity.
Clinical Evidence
In oncology RCTs, leucovorin (folinic acid) combined with 5-FU significantly improved response rates and overall survival compared to 5-FU alone in advanced colorectal cancer, establishing this combination as a standard palliative regimen; multiple meta-analyses confirmed this effect with hazard ratios favoring the combination. In methotrexate-based therapy (oncology and rheumatology), folinic acid rescue protocols have been validated in controlled trials to reduce grade 3-4 toxicities (mucositis, myelosuppression) without compromising antitumor efficacy when timed appropriately post-methotrexate infusion. For cerebral folate deficiency — a condition involving autoantibodies to folate receptors or impaired CSF folate transport — small case series (N=6–30) report clinically meaningful improvements in neurological symptoms with high-dose folinic acid supplementation, but no large RCTs have been completed. No adequately powered nutritional RCTs have evaluated folinic acid supplementation specifically for homocysteine lowering, MTHFR genotype management, or general folate status optimization in healthy adults, representing a significant evidence gap.
Safety & Interactions
Folinic acid is generally well-tolerated across therapeutic and nutritional dose ranges, with no established upper tolerable intake level for the active folate forms (as distinct from synthetic folic acid, which has a UL of 1,000 mcg/day for adults due to masking of B12 deficiency); adverse effects at nutritional supplement doses are rare and not well-characterized in controlled trials. Critical drug interaction: folinic acid should not be administered concurrently with methotrexate intended for therapeutic effect (e.g., cancer treatment), as it directly antagonizes methotrexate's mechanism; it is used intentionally as rescue therapy only after a defined post-methotrexate delay. Folinic acid may reduce the efficacy of other antifolate drugs including trimethoprim, pyrimethamine, and pemetrexed if co-administered; conversely, it may be prescribed alongside pyrimethamine in toxoplasmosis treatment to mitigate hematologic toxicity. Pregnancy safety: folate is essential for fetal neural tube development and folinic acid is considered appropriate for pregnant women, particularly those with impaired folic acid metabolism; however, high-dose supplementation beyond standard prenatal needs should be medically supervised, and B12 status should be assessed concurrently to avoid masking deficiency-related neurological damage.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
5-Formyl-5,6,7,8-tetrahydrofolic acidLeucovorinCitrovorum factorLevoleucovorin5-CHO-THFFolinicum
Frequently Asked Questions
What is the difference between folinic acid and folic acid?
Folic acid is a synthetic, oxidized form of vitamin B9 that requires conversion by dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) before becoming metabolically active — a process impaired in individuals with common MTHFR polymorphisms. Folinic acid is a naturally occurring, pre-reduced tetrahydrofolate derivative (5-formyl-THF) that bypasses both DHFR and MTHFR entirely, entering active one-carbon metabolism directly, making it bioavailable regardless of MTHFR genotype. For individuals with MTHFR C677T or A1298C variants who convert folic acid poorly, folinic acid or methylfolate (5-MTHF) are preferred supplemental forms.
Can folinic acid help with MTHFR gene mutations?
Yes, folinic acid is considered a viable supplemental folate for individuals with MTHFR polymorphisms because it does not require MTHFR enzymatic activity to become biologically active — it is already in a reduced, functional tetrahydrofolate form. Unlike synthetic folic acid, which can accumulate as unmetabolized folic acid (UMFA) in people with impaired MTHFR function, folinic acid enters the folate cycle directly and supports thymidylate synthesis, purine production, and homocysteine remethylation. While folinic acid and 5-methyltetrahydrofolate (5-MTHF) are both used for MTHFR support, no large head-to-head RCTs have definitively established superiority of one form over the other for this population.
What is folinic acid used for in cancer treatment?
In oncology, folinic acid (as leucovorin) serves two major roles: it rescues normal cells from toxicity following high-dose methotrexate therapy by replenishing intracellular tetrahydrofolate that methotrexate depleted, and it potentiates 5-fluorouracil (5-FU) cytotoxicity in colorectal cancer by elevating 5,10-methylenetetrahydrofolate levels, which stabilizes the inhibitory ternary complex between 5-FU's active metabolite (FdUMP) and thymidylate synthase. This combination is FDA-approved for palliative treatment of colorectal cancer, one of the most prevalent cancer types globally, and forms the backbone of regimens including FOLFOX and FOLFIRI. Dosing in this context is far higher (200–500 mg/m² IV) than nutritional supplementation and is administered under direct medical supervision.
What is the recommended dose of folinic acid as a supplement?
No official dietary reference intake or established tolerable upper limit has been set specifically for folinic acid as a supplement, as it is classified separately from synthetic folic acid in regulatory frameworks. In nutritional supplement contexts, folinic acid doses commonly range from 200 mcg to 1,000 mcg per day for general folate support or MTHFR-related folate repletion, often mirroring the 400–800 mcg/day folate recommendations for adults and pregnant women. In rheumatological practice, 5–25 mg/week of folinic acid is used to reduce methotrexate side effects; individuals with cerebral folate deficiency have been treated with higher doses (up to 2–5 mg/kg/day) in clinical case series, always under physician guidance.
Is folinic acid safe during pregnancy?
Folate is critically important during pregnancy for neural tube closure, fetal brain development, and rapid cell division, and folinic acid is considered an appropriate folate source for pregnant women, particularly those who carry MTHFR variants and may not efficiently activate synthetic folic acid. Standard prenatal supplementation of 400–800 mcg folate equivalents per day is well-established as safe and beneficial; folinic acid at these doses is not associated with known teratogenic effects. High-dose supplementation beyond standard prenatal recommendations should only be undertaken under medical supervision, and it is important to simultaneously assess vitamin B12 status, as adequate B12 is required for folate to function in homocysteine remethylation and neural development.
Does folinic acid interact with methotrexate or other medications?
Folinic acid is clinically used to counteract the toxic effects of methotrexate by replenishing folate cofactors after high-dose chemotherapy, a practice called 'folinic acid rescue.' If taking folinic acid supplements alongside other medications, consult your healthcare provider, as it may reduce efficacy of certain antifolate drugs used in cancer or autoimmune treatment. Additionally, some anticonvulsant medications may deplete folate levels, making folinic acid supplementation potentially beneficial when combined with these drugs.
Who benefits most from folinic acid supplementation instead of regular folic acid?
Individuals with confirmed MTHFR gene mutations (C677T or A1298C variants), those with impaired methylation capacity, or people with a history of neural tube defects may benefit more from folinic acid than standard folic acid supplements. Patients undergoing or recovering from methotrexate therapy also benefit significantly, as folinic acid directly restores active folate pools without requiring enzymatic conversion. People with certain genetic conditions affecting folate metabolism, such as cerebral folate deficiency, may also be better served by folinic acid supplementation under medical supervision.
How does folinic acid support one-carbon metabolism and methylation reactions?
Folinic acid (5-formyl-THF) serves as a direct donor of single-carbon units essential for DNA synthesis, neurotransmitter production, and methylation reactions that regulate gene expression and cellular function. By bypassing enzymatic bottlenecks in the folate cycle, it ensures adequate substrate availability for methyltransferase enzymes that depend on S-adenosyl methionine (SAM) cofactors. This support is particularly important for individuals with metabolic inefficiencies, as maintaining robust one-carbon metabolism is critical for immune function, energy production, and brain health.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w folinic-acid-5-formyl-tetrahydrofolic-acid curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
